Results 101 to 110 of about 222,704 (323)

Second-Generation Antipsychotics and Extrapyramidal Adverse Effects

BioMed Research International, 2014
Antipsychotic-induced extrapyramidal adverse effects are well recognized in the context of first-generation antipsychotic drugs. However, the introduction of second-generation antipsychotics, with atypical mechanism of action, especially lower dopamine ...
N. Divac, M. Prostran, I. Jakovcevski, Natasa Cerovac   +3 more
semanticscholar   +1 more source

Association of Neurodevelopmental Disorders and Congenital Anomalies With Prenatal Multiple Sclerosis Treatment—Real‐World Historical Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
There is a paucity of data regarding the effects of prenatal disease‐modifying therapies (DMTs) for multiple sclerosis (MS), on congenital anomalies in the offspring. Moreover, data on the association with neurodevelopmental disorders are lacking. This is an historical cohort study, within the Israeli Clalit Health Services database (2005–2024) that ...
Bar Rosh, Ofek Levi, Nili Stein, Amir Yahav, Naomi Gronich   +4 more
wiley   +1 more source

Association of typical and atypical antipsychotics with mortality in older adults with schizophrenia: a 5-year multicenter prospective study

Brazilian Journal of Psychiatry
Objective: Due to the uncertainty whether atypical and typical antipsychotics have a stronger association with mortality among older people with schizophrenia, we examined the rates and causes of mortality in older adults with schizophrenia who take ...
Raphaëlle Haddad, Marina Sánchez-Rico, Katayoun Rezaei, Sandra Abou Kassm, Carlos Blanco, Mark Olfson, Frédéric Limosin, Nicolas Hoertel   +7 more
doaj   +1 more source

The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study

BMC Psychiatry, 2018
Background Metabolic abnormalities are common in patients maintained on antipsychotics. These abnormalities increase the risk of cardiovascular diseases and mortality in this population.
Samer Hammoudeh, Suhaila Ghuloum, Ziyad Mahfoud, Arij Yehya, Abdulmoneim Abdulhakam, Azza Al-Mujalli, Mahmoud Al-Zirie, Mohamed Osman Abdel Rahman, Angela Godwin, Noura Younes, Yahya Hani, Dennis Mook-Kanamori, Marjonneke Mook-Kanamori, Reem El Sherbiny, Hassen Al-Amin   +14 more
doaj   +1 more source

The pharmacist’s response to the needs of patients undergoing treatment with psychotropic medication [PDF]

, 1999
The usage of psychotropic (Table 1) medication is considerable world wide. In Malta, this can be attested to by the numerous studies that have been conducted by the University of Malta Department of Pharmacy (in conjuction with other institutions and ...
Sant Fournier, Mary Ann
core  

Accelerating Generic Long‐Acting Antiretrovirals for Global HIV Treatment: Workshop Findings and a Roadmap to Access

Clinical Pharmacology &Therapeutics, EarlyView.
The global HIV response aims for widespread availability of affordable, quality‐assured long‐acting antiretroviral (LA ARV) drugs to achieve sustained epidemic control, particularly in low‐ and middle‐income countries. This report summarizes key discussion points, findings, and outcomes from an international workshop on generic LA ARVs, held in ...
Usman Arshad, Lobna Gaayeb, Henry Pertinez, Rajith K. R. Rajoli, Melynda Watkins, Parag Nimbolkar, Simone Perazzolo, Bharat Pagi, Annemarie Wensing, Saye Khoo, Marta Boffito, René Holm, Zack Panos, Imelda Mahaka, Francois Venter, Benny Kottiri, Keith W. Crawford, Rodney J. Y. Ho, Polly Clayden, Paul Domanico, Kimberly Struble, Andrew Owen, Charles Flexner   +22 more
wiley   +1 more source

Risk and protective factors for release in outpatients with schizophrenia [PDF]

, 2015
eposterWe aim to determine risk and protective factors influencing relapse incidence in outpatient with schizophrenia. A longitudinal, observational study was done with outpatients with schizophrenia (F20) or schizoaffective disorder (F25)(DMS-IV and ...
Bellido, M Victoria, Bellido-Estevez, Inmaculada, Blanco-Reina, Encarnacion, Gómez-Luque, A., Lopez, C   +4 more
core  

Advances in Human Mass Balance Studies: An IQ Consortium Perspective on Current Practices and Emerging Trends

Clinical Pharmacology &Therapeutics, EarlyView.
Human radiolabeled mass balance studies are crucial for comprehensively characterizing the absorption, distribution, metabolism, and excretion (ADME) of investigational drugs, providing essential data for drug development, regulatory evaluation, and product labeling.
Jason Boer, Ellen Cannady, Filip Cuyckens, Ulrike Glaenzel, Camille Granvil, Felix Huth, Alexander D. James, Wenying Li, Céline Veau, Graeme Young, Qin Yue, Gregory S. Walker, Upendra A. Argikar, Jonathan N. Bauman, Cathy Cantalloube, Yu‐Luan Chen, Ping Kang, Patricia Moliner, Mette L. Pedersen, Isabel Piel, Simone Schadt, Hanno Schieferstein, Julia Suchomel, Shuai Wang, S. Cyrus Khojasteh   +24 more
wiley   +1 more source

Leptin and psychiatric illnesses: does leptin play a role in antipsychotic-induced weight gain?

Lipids in Health and Disease, 2020
Antipsychotic-induced weight gain is the most prevalent somatic adverse event occurring in patients treated by antipsychotics, especially atypical antipsychotics.
Francky Teddy Endomba, Aurel T. Tankeu, Jan René Nkeck, Joel Noutakdie Tochie   +3 more
doaj   +1 more source

Denosumab Offers Relatively Lower Initial Protection Against Osteoporotic Vertebral Fractures in Treatment‐Naive Patients Compared With Zoledronate

Clinical Pharmacology &Therapeutics, EarlyView.
We compared the initial efficacy of denosumab (Dmab) and zoledronate (ZOL) in treatment‐naive patients with osteoporosis. This cohort study, based on TriNetX data, evaluated the risks of fractures and mortality using Kaplan–Meier survival analyses, with hazard ratios (HRs) and 95% confidence intervals (CIs).
Ko‐Hsiu Lu, Shiow‐Ing Wang, Shun‐Fa Yang   +2 more
wiley   +1 more source